Allergy Therapeutics

U.K. patent granted for sublingual vaccine

Published in Medicine and Law Weekly, January 14th, 2005

Allergy Therapeutics (AGY), the specialty pharmaceuticals company focused on allergy vaccines, announced it has been granted the first patent for its family of MPL-based sublingual vaccines, by the U.K. patent office.

Allergy Therapeutics believes a sublingual allergy vaccine has significant potential to capture market share from symptomatic treatments, such as antihistamines, as it could be self-administered at home and prescribed by general practitioners. Allergy Therapeutics is developing a sublingual vaccine incorporating MPL, which is at the proof of concept stage, the outcome of which is expected in the first half of 2005.

The patent is very...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medicine and Law Weekly

Source: Medicine and Law Weekly (2005-01-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry